Physician profile
William L Epperly
NPI 1477641645
$1,592.54
in general payments reported to CMS, 2019-2025
13 companies · $732 in 2025
The $732 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2021: $18.45 · 2022: $60.14 · 2023: $76.06 · 2024: $493 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $563.07 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Boston Scientific Corporation | $301.31 | 2025 | Apollo Esg System, Overstitch Endoscopic Suturing System |
| Amneal Pharmaceuticals LLC | $236.46 | 2022-2025 | Unithroid |
| Pacira Therapeutics, INC. | $102.17 | 2019 | |
| Therapeuticsmd, INC. | $97.20 | 2019 | |
| Ibsa Pharma INC. | $67.93 | 2019-2024 | Tirosint, Licart, Tirosint |
| Acella Pharmaceuticals, LLC | $59.81 | 2023-2025 | NP Thyroid 60 |
| Lilly USA, LLC | $56.80 | 2024 | Zepbound, Jardiance, Mounjaro |
| Exact Sciences Corporation | $27.42 | 2024 | Cologuard Collection Kit |
| Abbvie INC. | $24.82 | 2022 | |
| Astellas Pharma US INC | $23.35 | 2025 | Veozah |
| Antares Pharma, INC. | $17.89 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.31 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Epperly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.